Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three and six months ended June 30, 2008.

"As we've previously stated, we continue to increase our focus and resources on our proprietary programs that target large markets. Now we are beginning to see tangible results of that effort. Data from recent presentations at medical conferences validates the strength of our technology platform across multiple therapeutic areas," said Jonathan Lim, MD, President and CEO of Halozyme. "For example, Phase I clinical results showed faster absorption and onset for insulin when co-administered with our PH20 enzyme, a profile more similar to the body's own natural insulin. This could lead to the development of a best-in-class product. We have also demonstrated in animal models significant tumor suppression for PEGPH20 plus chemotherapy and controlled degradation of a structural component of the skin with HTI-501 that may prove beneficial in various dermatologic conditions. Over the next six months, we plan to initiate additional clinical trials to enhance the value of our pipeline."

Recent Scientific Achievements

-- Presentation of Phase I clinical results from the Company's diabetes

mellitus program at the American Diabetes Association's 68th Scientific

Sessions. The data showed that combining the Company's proprietary

recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R)

(regular insulin human) or Humalog(R) (insulin lispro) yielded

pharmacokinetics and glucodynamics that better mimicked
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... South Carolina (PRWEB) , ... August 05, 2015 ... ... first edition of the “Product Handbook – the complete product line.” The ... system components. , “This new product handbook consolidates our complete standard product offering ...
(Date:8/4/2015)... August 4, 2015 According ... Research, titled, "World Cardiac Biomarker - Market Opportunities, ... would generate the revenue of $2,085.9 million by ... to 2020. Cardiac Troponins (T, I) would continue ... due to high sensitivity and specificity. ...
(Date:8/4/2015)... , August 4, 2015 ... , online-only journal serving ... , a world-leading provider of scientific, technical, and medical ... the International Journal of Surgery Open ... journal covering all areas of surgery. This peer-reviewed, online-only ...
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White House will ... from across the United States to talk about their experiences with innovation and present ... to be among the attendees. , One of the day’s aims is to grow ...
Breaking Biology Technology:Spirax Sarco releases Product Handbook 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... SCOLR Pharma, Inc.,(Amex: DDD ) today announced that ... Annual Healthcare Conference to be held on November 10-12 ... Daniel O. Wilds, SCOLR Pharma,s President and CEO, ... on Tuesday, November 11,2008 at 12:00 p.m. ET. For ...
... today announced its lead sponsorship of the ... competition, held annually by the Massachusetts Institute ... brought together 84 undergraduate teams representing more ... Asia, Europe, Latin America, and the U.S. ...
... Renal Week 2008,November 4th through 9th,in Philadelphia, Pennsylvania, ... Medgenics,(AIM: MEDG), is pleased to announce encouraging preliminary ... landmark Phase I/II clinical trial of Medgenics, EPODURE ... with chronic kidney,disease, is underway. The current trial ...
Cached Biology Technology: The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 3Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 2Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 3Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 4Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia 5
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... warning signs of climate change in the upper atmosphere ... 2009 Tyler Prize for Environmental Achievement. The ... medals, will go to Richard Alley, professor of geosciences ... of atmospheric and climate sciences in the Scripps Institution ...
... researchers have won the American Physical Therapy Association,s award ... 2008. Their study focused on one of the ... cruciate ligament (ACL) injuries. Each year, nearly 250,000 ... of the major ligaments of the knee. The ...
... University of London have discovered that an ancient ... also explain how plants and algae control the ... (TCSTs) have long been recognised as the main ... changes in their environment. But recent research has ...
Cached Biology News:Winners of Tyler environmental prize announced 2Researchers win award for best clinical paper in orthopedic physical therapy 2
Transfection Buffer A & B Set 5 ml each...
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
... Includes gene gun unit, 5 O-rings, 5 barrel ... 9 V battery The Helios gene gun ... and direct gene transfer into a range of ... low-pressure helium pulse to sweep DNA- or RNA-coated ...
...
Biology Products: